Ehrlichia

Nagaraja R. Thirumalapura, David Walker

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Human ehrlichioses are emerging, often life-threating, tick-borne diseases caused by obligately intracellular Gram-negative bacteria belonging to the genus Ehrlichia. Ehrlichiae lack cell wall components, lipopolysaccharide and peptidoglycan. Ehrlichiae are maintained in the enzootic cycle involving persistently infected vertebrate hosts such as deer and the vector tick. Human monocytotropic ehrlichiosis (HME), caused by Ehrlichia chaffeensis, is highly prevalent in the south-central, southeastern and mid-Atlantic regions of the United States. Molecular and serological evidence suggest a worldwide distribution of ehrlichiae. Ehrlichia chaffeensis resides in monocytes and causes moderate-to-severe flu-like illness characterised by non-specific symptoms such as fever, headache, myalgia, etc. The disease can progress to a severe toxic-shock-like syndrome with multiorgan failure, liver injury, meningoencephalitis, acute respiratory distress syndrome and myocarditis. Aberrant host inflammatory responses are implicated in the disease pathogenesis. Frequent laboratory findings in HME patients include leukopenia, thrombocytopenia and elevated hepatic transaminases. Clinical diagnosis frequently requires application of appropriate molecular diagnostics. Ehrlichia ewingii and newly discovered Ehrlichia muris-like agent (EMLA) also cause human disease. Currently no vaccine is available against ehrlichiosis. Doxycycline is the drug of choice, and initiation of antibiotic therapy early during the infection is critical for its effectiveness.

Original languageEnglish (US)
Title of host publicationMolecular Medical Microbiology: Second Edition
PublisherElsevier Ltd
Pages2011-2032
Number of pages22
Volume3
ISBN (Print)9780123971692, 9780126775303
DOIs
StatePublished - Nov 26 2014

Fingerprint

Ehrlichia
Ehrlichiosis
Ehrlichia chaffeensis
Peptidoglycan
Doxycycline
Poisons
Mid-Atlantic Region
Transaminases
Liver
Tick-Borne Diseases
Lipopolysaccharides
Ixodes
Bacteria
Meningoencephalitis
Vaccines
Molecular Pathology
Myalgia
Adult Respiratory Distress Syndrome
Cells
Myocarditis

Keywords

  • Doxycycline
  • Ehrlichia
  • Ehrlichiosis
  • Immune-mediated pathology
  • Intracellular bacteria
  • Tick-borne pathogens

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Thirumalapura, N. R., & Walker, D. (2014). Ehrlichia. In Molecular Medical Microbiology: Second Edition (Vol. 3, pp. 2011-2032). Elsevier Ltd. https://doi.org/10.1016/B978-0-12-397169-2.00109-8

Ehrlichia. / Thirumalapura, Nagaraja R.; Walker, David.

Molecular Medical Microbiology: Second Edition. Vol. 3 Elsevier Ltd, 2014. p. 2011-2032.

Research output: Chapter in Book/Report/Conference proceedingChapter

Thirumalapura, NR & Walker, D 2014, Ehrlichia. in Molecular Medical Microbiology: Second Edition. vol. 3, Elsevier Ltd, pp. 2011-2032. https://doi.org/10.1016/B978-0-12-397169-2.00109-8
Thirumalapura NR, Walker D. Ehrlichia. In Molecular Medical Microbiology: Second Edition. Vol. 3. Elsevier Ltd. 2014. p. 2011-2032 https://doi.org/10.1016/B978-0-12-397169-2.00109-8
Thirumalapura, Nagaraja R. ; Walker, David. / Ehrlichia. Molecular Medical Microbiology: Second Edition. Vol. 3 Elsevier Ltd, 2014. pp. 2011-2032
@inbook{e4cce9c1195a49a394fa20a56142d99f,
title = "Ehrlichia",
abstract = "Human ehrlichioses are emerging, often life-threating, tick-borne diseases caused by obligately intracellular Gram-negative bacteria belonging to the genus Ehrlichia. Ehrlichiae lack cell wall components, lipopolysaccharide and peptidoglycan. Ehrlichiae are maintained in the enzootic cycle involving persistently infected vertebrate hosts such as deer and the vector tick. Human monocytotropic ehrlichiosis (HME), caused by Ehrlichia chaffeensis, is highly prevalent in the south-central, southeastern and mid-Atlantic regions of the United States. Molecular and serological evidence suggest a worldwide distribution of ehrlichiae. Ehrlichia chaffeensis resides in monocytes and causes moderate-to-severe flu-like illness characterised by non-specific symptoms such as fever, headache, myalgia, etc. The disease can progress to a severe toxic-shock-like syndrome with multiorgan failure, liver injury, meningoencephalitis, acute respiratory distress syndrome and myocarditis. Aberrant host inflammatory responses are implicated in the disease pathogenesis. Frequent laboratory findings in HME patients include leukopenia, thrombocytopenia and elevated hepatic transaminases. Clinical diagnosis frequently requires application of appropriate molecular diagnostics. Ehrlichia ewingii and newly discovered Ehrlichia muris-like agent (EMLA) also cause human disease. Currently no vaccine is available against ehrlichiosis. Doxycycline is the drug of choice, and initiation of antibiotic therapy early during the infection is critical for its effectiveness.",
keywords = "Doxycycline, Ehrlichia, Ehrlichiosis, Immune-mediated pathology, Intracellular bacteria, Tick-borne pathogens",
author = "Thirumalapura, {Nagaraja R.} and David Walker",
year = "2014",
month = "11",
day = "26",
doi = "10.1016/B978-0-12-397169-2.00109-8",
language = "English (US)",
isbn = "9780123971692",
volume = "3",
pages = "2011--2032",
booktitle = "Molecular Medical Microbiology: Second Edition",
publisher = "Elsevier Ltd",

}

TY - CHAP

T1 - Ehrlichia

AU - Thirumalapura, Nagaraja R.

AU - Walker, David

PY - 2014/11/26

Y1 - 2014/11/26

N2 - Human ehrlichioses are emerging, often life-threating, tick-borne diseases caused by obligately intracellular Gram-negative bacteria belonging to the genus Ehrlichia. Ehrlichiae lack cell wall components, lipopolysaccharide and peptidoglycan. Ehrlichiae are maintained in the enzootic cycle involving persistently infected vertebrate hosts such as deer and the vector tick. Human monocytotropic ehrlichiosis (HME), caused by Ehrlichia chaffeensis, is highly prevalent in the south-central, southeastern and mid-Atlantic regions of the United States. Molecular and serological evidence suggest a worldwide distribution of ehrlichiae. Ehrlichia chaffeensis resides in monocytes and causes moderate-to-severe flu-like illness characterised by non-specific symptoms such as fever, headache, myalgia, etc. The disease can progress to a severe toxic-shock-like syndrome with multiorgan failure, liver injury, meningoencephalitis, acute respiratory distress syndrome and myocarditis. Aberrant host inflammatory responses are implicated in the disease pathogenesis. Frequent laboratory findings in HME patients include leukopenia, thrombocytopenia and elevated hepatic transaminases. Clinical diagnosis frequently requires application of appropriate molecular diagnostics. Ehrlichia ewingii and newly discovered Ehrlichia muris-like agent (EMLA) also cause human disease. Currently no vaccine is available against ehrlichiosis. Doxycycline is the drug of choice, and initiation of antibiotic therapy early during the infection is critical for its effectiveness.

AB - Human ehrlichioses are emerging, often life-threating, tick-borne diseases caused by obligately intracellular Gram-negative bacteria belonging to the genus Ehrlichia. Ehrlichiae lack cell wall components, lipopolysaccharide and peptidoglycan. Ehrlichiae are maintained in the enzootic cycle involving persistently infected vertebrate hosts such as deer and the vector tick. Human monocytotropic ehrlichiosis (HME), caused by Ehrlichia chaffeensis, is highly prevalent in the south-central, southeastern and mid-Atlantic regions of the United States. Molecular and serological evidence suggest a worldwide distribution of ehrlichiae. Ehrlichia chaffeensis resides in monocytes and causes moderate-to-severe flu-like illness characterised by non-specific symptoms such as fever, headache, myalgia, etc. The disease can progress to a severe toxic-shock-like syndrome with multiorgan failure, liver injury, meningoencephalitis, acute respiratory distress syndrome and myocarditis. Aberrant host inflammatory responses are implicated in the disease pathogenesis. Frequent laboratory findings in HME patients include leukopenia, thrombocytopenia and elevated hepatic transaminases. Clinical diagnosis frequently requires application of appropriate molecular diagnostics. Ehrlichia ewingii and newly discovered Ehrlichia muris-like agent (EMLA) also cause human disease. Currently no vaccine is available against ehrlichiosis. Doxycycline is the drug of choice, and initiation of antibiotic therapy early during the infection is critical for its effectiveness.

KW - Doxycycline

KW - Ehrlichia

KW - Ehrlichiosis

KW - Immune-mediated pathology

KW - Intracellular bacteria

KW - Tick-borne pathogens

UR - http://www.scopus.com/inward/record.url?scp=84961138111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961138111&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-397169-2.00109-8

DO - 10.1016/B978-0-12-397169-2.00109-8

M3 - Chapter

AN - SCOPUS:84961138111

SN - 9780123971692

SN - 9780126775303

VL - 3

SP - 2011

EP - 2032

BT - Molecular Medical Microbiology: Second Edition

PB - Elsevier Ltd

ER -